1. Home
  2. List
Reference Patent

Reference - List

  • 9 Hits
  • Search Condition : Filter (MeSH = Antineoplastic Agents, Immunological / pharmacology)
Species Resource Title
Human and Animal Cells T24(RCB2536) , JMSU1(RCB2227) STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-γ-induced Apoptosis in Urothelial Cancer.
Human and Animal Cells Colon-26(RCB2657) , B16/BL6(RCB2638) Increasing Tumor Extracellular pH by an Oral Alkalinizing Agent Improves Antitumor Responses of Anti-PD-1 Antibody: Implication of Relationships between Serum Bicarbonate Concentrations, Urinary pH, and Therapeutic Outcomes.
Human and Animal Cells COLO205(RCB2127) , JHCOLOYI(RCB1706) , PMF-ko14(RCB1426) EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.
DNA material , Human and Animal Cells pCAmGCSF (RDB01522) , pCAZ 2 (RDB01870) , OV2944-HM-1(RCB1483) The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Human and Animal Cells TGBC2TKB(RCB1130) , TGBC14TKB(RCB1186) , TGBC24TKB(RCB1196) , TGBC18TKB(RCB1169) , TGBC50TKB(RCB1280) , TGBC51TKB(RCB1281) , TGBC52TKB(RCB1282) Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Human and Animal Cells CW-2(RCB0778) Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Human and Animal Cells Ba/F3(RCB0805) , A431 Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.
Human and Animal Cells LMSU(RCB1062) Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis.
Human and Animal Cells 293T(RCB2202) Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.